

U.S. Patent Application Serial No. 10/525,298
Reply to Notice of Non-Compliant Amendment of June 5, 2006

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (original) A method of treating cancer in a patient comprising administering to the patient an amount of oxaliplatin in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have a synergistic anticancer effect.
2. (original) A method according to claim 1 wherein in addition to oxaliplatin other chemotherapeutic agents are also delivered to the patient with the oxaliplatin.
3. (original) A method according to claim 2 wherein an effective anticancer amount of 5-FU and or LV are administered with oxaliplatin or a oxaliplatin based therapy'
4. (original) A method according to claim 2 wherein other chemotherapeutic agents that may be employed in the method include systemic chemotherapy drugs such as irinotecan or capecitabine.
5. (currently amended) A method according to ~~anyone of the preceding claims~~ claim 1 wherein the patient is also treated with an anti-angiogenesis factor.
6. (currently amended) A method according to ~~anyone of the preceding claims~~ claim 1 wherein the patient is also treated with other anticancer agents including antibodies targeted against a cancer cells or the blood vessels supplying the cancer cells or antibodies targeting EGF and VEGF.
7. (currently amended) A therapeutic combination of anticancer agents comprising an effectively therapeutic amount of oxaliplatin and an amount of radionuclide-doped agent suitable

U.S. Patent Application Serial No. 10/525,298
Reply to Notice of Non-Compliant Amendment of June 5, 2006

for SIRT to effectively treat a cancer, ~~characterised in that~~ wherein the combination when administered to a patient leads two therapies when administered to a patient lead to a synergistic anticancer effect that is therapeutically more efficacious than either treatment when administered alone.

8. (original) A therapeutic composition according to 7 wherein oxaliplatin is combined with 5-fluorouracil and leucovorin.

9. (original) A therapeutic composition according to 8 wherein oxaliplatin is combined with other systemic chemotherapy drugs such as irinotecan or capecitabine.

10. (original) A therapeutic composition according to 8 wherein oxaliplatin is combined with an anti-angiogenesis factor.

11. (original) A therapeutic composition according to 8 wherein oxaliplatin is combined with an anticancer agent including antibodies targeted against a cancer cells or the blood vessels supplying the cancer cells or antibodies targeting EGF and VEGF.

12. (canceled)

13. (New) The method according to claim 1 wherein the cancer is a primary or secondary cancer.